A portable electronic nose can effectively detect precursors of oesophageal cancer, report researchers from the Radboud university medical center in the medical science journal GUT. This was demonstrated in an initial study involving more than four hundred patients. In time, this inexpensive and non-invasive technique may be used diagnostically to detect the precursor of oesophageal cancer (Barrett’s oesophagus) in general practice.
The number of cases of oesophageal cancer and its precursor - Barrett's oesophagus - has increased enormously in recent decades. The disease is usually diagnosed late and at an advanced stage, which makes treatment difficult. Barrett’s oesophagus is a pre-stage of oesophageal cancer, in which healthy, white-coloured cells at the base of the oesophagus have been replaced by aberrant, pink cells. The diagnosis of Barrett's oesophagus is done by using an endoscope with a camera that enters the oesophagus. An unpleasant and expensive procedure, which is poorly suited for population screening.
Researchers from Radboud university medical center, Bernhoven and CWZ therefore took a closer look at a less expensive and less cumbersome option. They investigated whether good diagnoses are possible with a portable electronic nose. An e-Nose, which measures volatile organic compounds (VOC) in exhaled air. These gaseous compounds are formed during all kinds of metabolic processes in the body. The idea is that changes in metabolism also lead to a different mix of these compounds. In this manner, you could measure inflammation through exhaled air, for instance, but also abnormal activities in the cells, thanks to the characteristic profiles that accompany them. The question is, how well could you smell Barrett’s oesophagus using such an e-Nose?
Of the more than 400 patients who participated in the study, 129 had Barrett's oesophagus and 141 had reflux (gastric acid returning to the oesophagus). 132 patients functioned as controls. Yonne Peters, Gastroenterologist researcher at Radboudumc: "After analysis, we saw markedly different exhalation profiles for these three groups. The sensitivity to detecting Barrett's oesophagus was high, namely 91 percent. This means that the test detects 91 out of 100 people with Barrett's oesophagus based on their exhalation profile. Selection of people who don't have Barrett's oesophagus - the specificity - is 74 percent."
"These figures are comparable to breast and colon cancer screening,” says gastroenterologist and research coordinator Peter Siersema. "After these encouraging results, further research among larger groups of people is obviously needed. If these results persist, its user-friendliness and low cost could contribute to making this breathalyser test interesting for non-invasive screening of Barrett's oesophagus by general practitioners."
Publication in GUT Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device
Yonne Peters, Ruud W M Schrauwen, Adriaan C Tan, Sanne K Bogers, Bart de Jong, Peter D Siersema
Related news items
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.read more
Oral health research makes significant impact at the 148th WHO Executive Board meeting25 January 2021
During the 148th session of the World Health Organization (WHO) Executive Board meeting, Member States passed a game-changing resolution on oral health. WHO Director General Dr Tedros Adhanom Ghebreyesus called it a “landmark resolution”.read more
Radboud Young Academy safeguards the future of science21 January 2021
New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.read more
Increase radio- and immunotherapy efficacy by targeting hypoxia21 January 2021
In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.read more
Radiation boost lowers risk of prostate cancer recurrence21 January 2021
An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.read more
New research through grants for Radboudumc researchers14 January 2021
Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.read more